DOT1L: a key target in normal chromatin remodelling and in mixed-lineage leukaemia treatment

References

• Biswas S, Rao CM. Epigenetic tools (The writers, the readers and the erasers) and their implications in cancer therapy. Eur J Pharmacol. 2018 Oct;15(837):8–24.
   Google Scholar
• Trievel RC. Structure and function of histone methyltransferases. Crit Rev Eukaryot Gene Expr. 2004;14(3):147–169.
   PubMed Web of Science ®Google Scholar
• Greciano PG, Goday C. Methylation of histone H3 at Lys4 differs between paternal and maternal chromosomes in Sciara ocellaris germline development. J Cell Sci. 2006 Nov 15;119(Pt 22):4667–4677.
   PubMed Web of Science ®Google Scholar
• Brinkman AB, Roelofsen T, Pennings SW, et al. Histone modification patterns associated with the human X chromosome. EMBO Rep. 2006 Jun;7(6):628–634.
   PubMed Web of Science ®Google Scholar
• Kari V, Raul SK, Henck JM, et al. The histone methyltransferase DOT1L is required for proper DNA damage response, DNA repair, and modulates chemotherapy responsiveness. Clin Epigenetics. 2019 Jan 7;11(1):4.
   PubMedGoogle Scholar
• Eom GH, Kim KB, Kim JH, et al. Histone methyltransferase SETD3 regulates muscle differentiation. J Biol Chem. 2011 Oct 7;286(40):34733–34742.
   PubMed Web of Science ®Google Scholar
• Chen X, Cao G, Wu J, et al. The histone methyltransferase EZH2 primes the early differentiation of follicular helper T cells during acute viral infection. Cell Mol Immunol. 2019. doi:10.1038/s41423-019-0219-z.
   Web of Science ®Google Scholar
• Chen Y, Liu X, Li Y, et al. Lung cancer therapy targeting histone methylation: opportunities and challenges. Comput Struct Biotechnol J. 2018;16:211–223.
   PubMed Web of Science ®Google Scholar
• Tran TQ, Lowman XH, Kong M. Molecular pathways: metabolic control of histone methylation and gene expression in cancer. Clin Cancer Res. 2017 Aug 1;23(15):4004–4009.
   PubMed Web of Science ®Google Scholar
• Wilson S, Fan L, Sahgal N, et al. The histone demethylase KDM3A regulates the transcriptional program of the androgen receptor in prostate cancer cells. Oncotarget. 2017 May 2;8(18):30328–30343.
   PubMedGoogle Scholar
• Li T, Chen H, Li W, et al. Promoter histone H3K27 methylation in the control of IGF2 imprinting in human tumor cell lines. Hum Mol Genet. 2014 Jan 1;23(1):117–128.
   PubMed Web of Science ®Google Scholar
• Shen NY, Ng SY, Toepp SL, et al. Protein arginine methyltransferase expression and activity during myogenesis. Biosci Rep. 2018 Feb 28;38(1):1–17.
   Google Scholar
• Wei H, Mundade R, Lange KC, et al. Protein arginine methylation of non-histone proteins and its role in diseases. Cell Cycle. 2014;13(1):32–41.
   PubMed Web of Science ®Google Scholar
• Black JC, Van Rechem C, Whetstine JR. Histone lysine methylation dynamics: establishment, regulation, and biological impact. Mol Cell. 2012 Nov 30;48(4):491–507.
   PubMed Web of Science ®Google Scholar
• Rea S, Eisenhaber F, O’Carroll D, et al. Regulation of chromatin structure by site-specific histone H3 methyltransferases. Nature. 2000 Aug 10;406(6796):593–599.
   PubMed Web of Science ®Google Scholar
• Shilatifard A. Molecular implementation and physiological roles for histone H3 lysine 4 (H3K4) methylation. Curr Opin Cell Biol. 2008 Jun;20(3):341–348.
   PubMed Web of Science ®Google Scholar
• Dillon SC, Zhang X, Trievel RC, et al. The SET-domain protein superfamily: protein lysine methyltransferases. Genome Biol. 2005;6(8):227.
   PubMed Web of Science ®Google Scholar
• Wu H, Zeng H, Dong A, et al. Structure of the catalytic domain of EZH2 reveals conformational plasticity in cofactor and substrate binding sites and explains oncogenic mutations. PLoS One. 2013;8(12):e83737.
   PubMed Web of Science ®Google Scholar
• Kleer CG, Cao Q, Varambally S, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11606–11611.
   PubMed Web of Science ®Google Scholar
• Takawa M, Masuda K, Kunizaki M, et al. Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker. Cancer Sci. 2011 Jul;102(7):1298–1305.
   PubMed Web of Science ®Google Scholar
• Varambally S, Cao Q, Mani RS, et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science. 2008 Dec 12;322(5908):1695–1699.
   PubMed Web of Science ®Google Scholar
• Knutson SK, Wigle TJ, Warholic NM, et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol. 2012 Nov;8(11):890–896.
   PubMed Web of Science ®Google Scholar
• Konze KD, Ma A, Li F, et al. An orally bioavailable chemical probe of the lysine methyltransferases EZH2 and EZH1. ACS Chem Biol. 2013;8(6):1324–1334.
   PubMed Web of Science ®Google Scholar
• Qi W, Chan H, Teng L, et al. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl Acad Sci U S A. 2012 Dec 26;109(52):21360–21365.
   PubMed Web of Science ®Google Scholar
• Struck AW, Thompson ML, Wong LS, et al. S-adenosyl-methionine-dependent methyltransferases: highly versatile enzymes in biocatalysis, biosynthesis and other biotechnological applications. Chembiochem. 2012 Dec 21;13(18):2642–2655.
   PubMed Web of Science ®Google Scholar
• Steger DJ, Lefterova MI, Ying L, et al. DOT1L/KMT4 recruitment and H3K79 methylation are ubiquitously coupled with gene transcription in mammalian cells. Mol Cell Biol. 2008 Apr;28(8):2825–2839.
   PubMed Web of Science ®Google Scholar
• Annala M, Kivinummi K, Leinonen K, et al. DOT1L-HES6 fusion drives androgen independent growth in prostate cancer. EMBO Mol Med. 2014 Sep;6(9):1121–1123.
   PubMed Web of Science ®Google Scholar
• Nassa G, Salvati A, Tarallo R, et al. Inhibition of histone methyltransferase DOT1L silences ERalpha gene and blocks proliferation of antiestrogen-resistant breast cancer cells. Sci Adv. 2019 Feb;5(2):eaav5590.
   PubMed Web of Science ®Google Scholar
• Lee JY, Kong G. DOT1L: a new therapeutic target for aggressive breast cancer. Oncotarget. 2015 Oct 13;6(31):30451–30452.
   PubMedGoogle Scholar
• Wang X, Wang H, Xu B, et al. Depletion of H3K79 methyltransferase Dot1L promotes cell invasion and cancer stem-like cell property in ovarian cancer. Am J Transl Res. 2019;11(2):1145–1153.
   PubMed Web of Science ®Google Scholar
• Okuda H, Stanojevic B, Kanai A, et al. Cooperative gene activation by AF4 and DOT1L drives MLL-rearranged leukemia. J Clin Invest. 2017 May 1;127(5):1918–1931.
   PubMed Web of Science ®Google Scholar
• Liu W, Deng L, Song Y, et al. DOT1L inhibition sensitizes MLL-rearranged AML to chemotherapy. PLoS One. 2014;9(5):e98270.
   PubMed Web of Science ®Google Scholar
• Meyer C, Burmeister T, Groger D, et al. The MLL recombinome of acute leukemias in 2017. Leukemia. 2018 Feb;32(2):273–284.
   PubMed Web of Science ®Google Scholar
• Kong X, Ouyang S, Liang Z, et al. Catalytic mechanism investigation of lysine-specific demethylase 1 (LSD1): a computational study. PLoS One. 2011;6(9):e25444.
   PubMed Web of Science ®Google Scholar
• Hayward D, Cole PA. LSD1 histone demethylase assays and inhibition. Methods Enzymol. 2016;573:261–278.
   PubMed Web of Science ®Google Scholar
• Accari SL, Fisher PR. Emerging roles of JmjC domain-containing proteins. Int Rev Cell Mol Biol. 2015;319:165–220.
   PubMed Web of Science ®Google Scholar
• Singer MS, Kahana A, Wolf AJ, et al. Identification of high-copy disruptors of telomeric silencing in Saccharomyces cerevisiae. Genetics. 1998 Oct;150(2):613–632.
   PubMed Web of Science ®Google Scholar
• Chen S, Li L, Chen Y, et al. Identification of novel disruptor of telomeric silencing 1-like (DOT1L) inhibitors through structure-based virtual screening and biological assays. J Chem Inf Model. 2016 Mar 28;56(3):527–534.
   PubMed Web of Science ®Google Scholar
• Min J, Feng Q, Li Z, et al. Structure of the catalytic domain of human DOT1L, a non-SET domain nucleosomal histone methyltransferase. Cell. 2003 Mar 7;112(5):711–723.
   PubMed Web of Science ®Google Scholar
• Feng Q, Wang H, Ng HH, et al. Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain. Curr Biol. 2002 Jun 25;12(12):1052–1058.
   PubMed Web of Science ®Google Scholar
• Schubeler D, MacAlpine DM, Scalzo D, et al. The histone modification pattern of active genes revealed through genome-wide chromatin analysis of a higher eukaryote. Genes Dev. 2004 Jun 1;18(11):1263–1271.
   PubMed Web of Science ®Google Scholar
• List O, Togawa T, Tsuda M, et al. Overexpression of grappa encoding a histone methyltransferase enhances stress resistance in Drosophila. Hereditas. 2009 Feb;146(1):19–28.
   PubMed Web of Science ®Google Scholar
• Janzen CJ, Hake SB, Lowell JE, et al. Selective di- or trimethylation of histone H3 lysine 76 by two DOT1 homologs is important for cell cycle regulation in Trypanosoma brucei. Mol Cell. 2006 Aug;23(4):497–507.
   PubMed Web of Science ®Google Scholar
• Frederiks F, Tzouros M, Oudgenoeg G, et al. Nonprocessive methylation by Dot1 leads to functional redundancy of histone H3K79 methylation states. Nat Struct Mol Biol. 2008 Jun;15(6):550–557.
   PubMed Web of Science ®Google Scholar
• van Leeuwen F, Gafken PR, Gottschling DE. Dot1p modulates silencing in yeast by methylation of the nucleosome core. Cell. 2002 Jun 14;109(6):745–756.
   PubMed Web of Science ®Google Scholar
• Jones B, Su H, Bhat A, et al. The histone H3K79 methyltransferase Dot1L is essential for mammalian development and heterochromatin structure. PLoS Genet. 2008 Sep 12;4(9):e1000190.
   PubMed Web of Science ®Google Scholar
• Lacoste N, Utley RT, Hunter JM, et al. Disruptor of telomeric silencing-1 is a chromatin-specific histone H3 methyltransferase. J Biol Chem. 2002 Aug 23;277(34):30421–30424.
   PubMed Web of Science ®Google Scholar
• Ng HH, Xu RM, Zhang Y, et al. Ubiquitination of histone H2B by Rad6 is required for efficient Dot1-mediated methylation of histone H3 lysine 79. J Biol Chem. 2002 Sep 20;277(38):34655–34657.
   PubMed Web of Science ®Google Scholar
• Vlaming H, McLean CM, Korthout T, et al. Conserved crosstalk between histone deacetylation and H3K79 methylation generates DOT1L-dose dependency in HDAC1-deficient thymic lymphoma. Embo J. 2019 Jun 17;38:1–14.
   Web of Science ®Google Scholar
• Shahbazian MD, Zhang K, Grunstein M. Histone H2B ubiquitylation controls processive methylation but not monomethylation by Dot1 and Set1. Mol Cell. 2005 Jul 22;19(2):271–277.
   PubMed Web of Science ®Google Scholar
• Hwang WW, Venkatasubrahmanyam S, Ianculescu AG, et al. A conserved RING finger protein required for histone H2B monoubiquitination and cell size control. Mol Cell. 2003 Jan;11(1):261–266.
   PubMed Web of Science ®Google Scholar
• Wood A, Krogan NJ, Dover J, et al. Bre1, an E3 ubiquitin ligase required for recruitment and substrate selection of Rad6 at a promoter. Mol Cell. 2003 Jan;11(1):267–274.
   PubMed Web of Science ®Google Scholar
• Xiao T, Kao CF, Krogan NJ, et al. Histone H2B ubiquitylation is associated with elongating RNA polymerase II. Mol Cell Biol. 2005 Jan;25(2):637–651.
   PubMed Web of Science ®Google Scholar
• Sun ZW, Allis CD. Ubiquitination of histone H2B regulates H3 methylation and gene silencing in yeast. Nature. 2002 Jul 4;418(6893):104–108.
   PubMed Web of Science ®Google Scholar
• Luger K, Mader AW, Richmond RK, et al. Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature. 1997 Sep 18;389(6648):251–260.
   PubMed Web of Science ®Google Scholar
• McGinty RK, Kim J, Chatterjee C, et al. Chemically ubiquitylated histone H2B stimulates hDot1L-mediated intranucleosomal methylation. Nature. 2008 Jun 5;453(7196):812–816.
   PubMed Web of Science ®Google Scholar
• Manning BJ, Peterson CL. Direct interactions promote eviction of the Sir3 heterochromatin protein by the SWI/SNF chromatin remodeling enzyme. Proc Natl Acad Sci U S A. 2014 Dec 16;111(50):17827–17832.
   PubMed Web of Science ®Google Scholar
• Grunstein M, Gasser SM. Epigenetics in Saccharomyces cerevisiae. Cold Spring Harb Perspect Biol. 2013 Jul 1;5(7):a017491-a017491.
   PubMed Web of Science ®Google Scholar
• Bupp JM, Martin AE, Stensrud ES, et al. Telomere anchoring at the nuclear periphery requires the budding yeast Sad1-UNC-84 domain protein Mps3. J Cell Biol. 2007 Dec 3;179(5):845–854.
   PubMed Web of Science ®Google Scholar
• Anderson CJ, Baird MR, Hsu A, et al. Structural basis for recognition of ubiquitylated nucleosome by Dot1L methyltransferase. Cell Rep. 2019 Feb 12;26(7):1681–1690 e5.
   PubMed Web of Science ®Google Scholar
• Moretti P, Freeman K, Coodly L, et al. Evidence that a complex of SIR proteins interacts with the silencer and telomere-binding protein RAP1. Genes Dev. 1994 Oct 1;8(19):2257–2269.
   PubMed Web of Science ®Google Scholar
• Imai S, Armstrong CM, Kaeberlein M, et al. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature. 2000 Feb 17;403(6771):795–800.
   PubMed Web of Science ®Google Scholar
• Palladino F, Laroche T, Gilson E, et al. SIR3 and SIR4 proteins are required for the positioning and integrity of yeast telomeres. Cell. 1993 Nov 5;75(3):543–555.
   PubMed Web of Science ®Google Scholar
• Smith JS, Boeke JD. An unusual form of transcriptional silencing in yeast ribosomal DNA. Genes Dev. 1997 Jan 15;11(2):241–254.
   PubMed Web of Science ®Google Scholar
• Rossmann MP, Luo W, Tsaponina O, et al. A common telomeric gene silencing assay is affected by nucleotide metabolism. Mol Cell. 2011 Apr 8;42(1):127–136.
   PubMed Web of Science ®Google Scholar
• Takahashi YH, Schulze JM, Jackson J, et al. Dot1 and histone H3K79 methylation in natural telomeric and HM silencing. Mol Cell. 2011 Apr 8;42(1):118–126.
   PubMed Web of Science ®Google Scholar
• Kim W, Kim R, Park G, et al. Deficiency of H3K79 histone methyltransferase Dot1-like protein (DOT1L) inhibits cell proliferation. J Biol Chem. 2012 Feb 17;287(8):5588–5599.
   PubMed Web of Science ®Google Scholar
• Price BD, D’Andrea AD. Chromatin remodeling at DNA double-strand breaks. Cell. 2013 Mar 14;152(6):1344–1354.
   PubMed Web of Science ®Google Scholar
• Rappold I, Iwabuchi K, Date T, et al. Tumor suppressor p53 binding protein 1 (53BP1) is involved in DNA damage-signaling pathways. J Cell Biol. 2001 Apr 30;153(3):613–620.
   PubMed Web of Science ®Google Scholar
• Jorgensen S, Schotta G, Sorensen CS. Histone H4 lysine 20 methylation: key player in epigenetic regulation of genomic integrity. Nucleic Acids Res. 2013 Mar 1;41(5):2797–2806.
   PubMed Web of Science ®Google Scholar
• Lazzaro F, Sapountzi V, Granata M, et al. Histone methyltransferase Dot1 and Rad9 inhibit single-stranded DNA accumulation at DSBs and uncapped telomeres. Embo J. 2008 May 21;27(10):1502–1512.
   PubMed Web of Science ®Google Scholar
• Wakeman TP, Wang Q, Feng J, et al. Bat3 facilitates H3K79 dimethylation by DOT1L and promotes DNA damage-induced 53BP1 foci at G1/G2 cell-cycle phases. Embo J. 2012 May 2;31(9):2169–2181.
   PubMed Web of Science ®Google Scholar
• Geuting V, Reul C, Lobrich M. ATM release at resected double-strand breaks provides heterochromatin reconstitution to facilitate homologous recombination. PLoS Genet. 2013;9(8):e1003667.
   PubMed Web of Science ®Google Scholar
• Zhu B, Chen S, Wang H, et al. The protective role of DOT1L in UV-induced melanomagenesis. Nat Commun. 2018 Jan 17;9(1):259.
   PubMedGoogle Scholar
• De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J. 2016 Jul 1;6(7):e441.
   PubMed Web of Science ®Google Scholar
• Jamieson CH. Chronic myeloid leukemia stem cells. Hematology Am Soc Hematol Educ Program. 2008;2008:436–442.
   Google Scholar
• Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med. 1999 Sep 30;341(14):1051–1062.
   PubMed Web of Science ®Google Scholar
• Oriol A, Vives S, Hernandez-Rivas JM, et al. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. Haematologica. 2010 Apr;95(4):589–596.
   PubMed Web of Science ®Google Scholar
• Pulte D, Jansen L, Gondos A, et al. Survival of adults with acute lymphoblastic leukemia in Germany and the United States. PLoS One. 2014;9(1):e85554.
   PubMed Web of Science ®Google Scholar
• Chen CW, Armstrong SA. Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyond. Exp Hematol. 2015 Aug;43(8):673–684.
   PubMed Web of Science ®Google Scholar
• Marchesi F, Girardi K, Avvisati G. Pathogenetic, clinical, and prognostic features of adult t(4;11)(q21;q23)/MLL-AF4 positive B-cell acute lymphoblastic leukemia. Adv Hematol. 2011;2011:621627.
   PubMedGoogle Scholar
• Heerema NA, Sather HN, Ge J, et al. Cytogenetic studies of infant acute lymphoblastic leukemia: poor prognosis of infants with t(4;11) - a report of the Children’s Cancer Group. Leukemia. 1999 May;13(5):679–686.
   PubMed Web of Science ®Google Scholar
• Balgobind BV, Zwaan CM, Pieters R, et al. The heterogeneity of pediatric MLL-rearranged acute myeloid leukemia. Leukemia. 2011 Aug;25(8):1239–1248.
   PubMed Web of Science ®Google Scholar
• Raimondi SC, Chang MN, Ravindranath Y, et al. Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative pediatric oncology group study-POG 8821. Blood. 1999 Dec 1;94(11):3707–3716.
   PubMed Web of Science ®Google Scholar
• Schoch C, Schnittger S, Klaus M, et al. AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases. Blood. 2003 Oct 1;102(7):2395–2402.
   PubMed Web of Science ®Google Scholar
• Gu Y, Nakamura T, Alder H, et al. The t(4;11) chromosome translocation of human acute leukemias fuses the ALL-1 gene, related to Drosophila trithorax, to the AF-4 gene. Cell. 1992 Nov 13;71(4):701–708.
   PubMed Web of Science ®Google Scholar
• Tkachuk DC, Kohler S, Cleary ML. Involvement of a homolog of Drosophila trithorax by 11q23 chromosomal translocations in acute leukemias. Cell. 1992 Nov 13;71(4):691–700.
   PubMed Web of Science ®Google Scholar
• Bursen A, Schwabe K, Ruster B, et al. The AF4.MLL fusion protein is capable of inducing ALL in mice without requirement of MLL.AF4. Blood. 2010 Apr 29;115(17):3570–3579.
   PubMed Web of Science ®Google Scholar
• Wachter K, Kowarz E, Marschalek R. Functional characterisation of different MLL fusion proteins by using inducible sleeping beauty vectors. Cancer Lett. 2014 Oct 1;352(2):196–202.
   PubMed Web of Science ®Google Scholar
• Ma C, Staudt LM. LAF-4 encodes a lymphoid nuclear protein with transactivation potential that is homologous to AF-4, the gene fused to MLL in t(4;11) leukemias. Blood. 1996 Jan 15;87(2):734–745.
   PubMed Web of Science ®Google Scholar
• Li Y, Wen H, Xi Y, et al. AF9 YEATS domain links histone acetylation to DOT1L-mediated H3K79 methylation. Cell. 2014 Oct 23;159(3):558–571.
   PubMed Web of Science ®Google Scholar
• Domer PH, Fakharzadeh SS, Chen CS, et al. Acute mixed-lineage leukemia t(4;11)(q21;q23) generates an MLL-AF4 fusion product. Proc Natl Acad Sci U S A. 1993 Aug 15;90(16):7884–7888.
   PubMed Web of Science ®Google Scholar
• Meyer C, Hofmann J, Burmeister T, et al. The MLL recombinome of acute leukemias in 2013. Leukemia. 2013 Nov;27(11):2165–2176.
   PubMed Web of Science ®Google Scholar
• Iida S, Seto M, Yamamoto K, et al. MLLT3 gene on 9p22 involved in t(9;11) leukemia encodes a serine/proline rich protein homologous to MLLT1 on 19p13. Oncogene. 1993 Nov;8(11):3085–3092.
   PubMed Web of Science ®Google Scholar
• Okada Y, Feng Q, Lin Y, et al. hDOT1L links histone methylation to leukemogenesis. Cell. 2005 Apr 22;121(2):167–178.
   PubMed Web of Science ®Google Scholar
• Milne TA, Martin ME, Brock HW, et al. Leukemogenic MLL fusion proteins bind across a broad region of the Hox a9 locus, promoting transcription and multiple histone modifications. Cancer Res. 2005 Dec 15;65(24):11367–11374.
   PubMed Web of Science ®Google Scholar
• Guenther MG, Lawton LN, Rozovskaia T, et al. Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia. Genes Dev. 2008 Dec 15;22(24):3403–3408.
   PubMed Web of Science ®Google Scholar
• Thiel AT, Blessington P, Zou T, et al. MLL-AF9-induced leukemogenesis requires coexpression of the wild-type Mll allele. Cancer Cell. 2010 Feb 17;17(2):148–159.
   PubMed Web of Science ®Google Scholar
• Wong P, Iwasaki M, Somervaille TC, et al. Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential. Genes Dev. 2007 Nov 1;21(21):2762–2774.
   PubMed Web of Science ®Google Scholar
• Mueller D, Bach C, Zeisig D, et al. A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification. Blood. 2007 Dec 15;110(13):4445–4454.
   PubMed Web of Science ®Google Scholar
• Zhang H, Zhou B, Qin S, et al. Structural and functional analysis of the DOT1L-AF10 complex reveals mechanistic insights into MLL-AF10-associated leukemogenesis. Genes Dev. 2018 Mar 1;32(5–6):341–346.
   PubMed Web of Science ®Google Scholar
• Nguyen AT, Taranova O, He J, et al. DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis. Blood. 2011 Jun 23;117(25):6912–6922.
   PubMed Web of Science ®Google Scholar
• Daigle SR, Olhava EJ, Therkelsen CA, et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell. 2011 Jul 12;20(1):53–65.
   PubMed Web of Science ®Google Scholar
• Daigle SR, Olhava EJ, Therkelsen CA, et al. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood. 2013 Aug 8;122(6):1017–1025.
   PubMed Web of Science ®Google Scholar
• Waters NJ, Daigle SR, Rehlaender BN, et al. Exploring drug delivery for the DOT1L inhibitor pinometostat (EPZ-5676): subcutaneous administration as an alternative to continuous IV infusion, in the pursuit of an epigenetic target. J Control Release. 2015 Dec 28;220(Pt B):758–765.
   PubMedGoogle Scholar
• Stein EM, Garcia-Manero G, Rizzieri DA, et al. The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia. Blood. 2018 Jun 14;131(24):2661–2669.
   PubMed Web of Science ®Google Scholar
• Neerav Shukla M, CW MD PhD, MMOB MD, et al. Final report of phase 1 study of the DOT1L inhibitor, pinometostat (EPZ-5676), in children with relapsed or refractory MLL-r acute leukemia. blood. 2016 december 2;128(22):2175–2178.
   Web of Science ®Google Scholar
• Nguyen AT, He J, Taranova O, et al. Essential role of DOT1L in maintaining normal adult hematopoiesis. Cell Res. 2011 Sep;21(9):1370–1373.
   PubMed Web of Science ®Google Scholar
• Jo SY, Granowicz EM, Maillard I, et al. Requirement for Dot1l in murine postnatal hematopoiesis and leukemogenesis by MLL translocation. Blood. 2011 May 5;117(18):4759–4768.
   PubMed Web of Science ®Google Scholar
• Du L, Grigsby SM, Yao A, et al. Peptidomimetics for targeting protein-protein interactions between DOT1L and MLL oncofusion proteins AF9 and ENL. ACS Med Chem Lett. 2018 Sep 13;9(9):895–900.
   PubMed Web of Science ®Google Scholar
• Yao Y, Chen P, Diao J, et al. Selective inhibitors of histone methyltransferase DOT1L: design, synthesis, and crystallographic studies. J Am Chem Soc. 2011 Oct 26;133(42):16746–16749.
   PubMed Web of Science ®Google Scholar
• Yu W, Smil D, Li F, et al. Bromo-deaza-SAH: a potent and selective DOT1L inhibitor. Bioorg Med Chem. 2013 Apr 1;21(7):1787–1794.
   PubMed Web of Science ®Google Scholar
• Chen C, Zhu H, Stauffer F, et al. Discovery of novel Dot1L inhibitors through a structure-based fragmentation approach. ACS Med Chem Lett. 2016 Aug 11;7(8):735–740.
   PubMed Web of Science ®Google Scholar
• Anglin JL, Song Y. A medicinal chemistry perspective for targeting histone H3 lysine-79 methyltransferase DOT1L. J Med Chem. 2013 Nov 27;56(22):8972–8983.
   PubMed Web of Science ®Google Scholar
• Yu W, Chory EJ, Wernimont AK, et al. Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors. Nat Commun. 2012;3:1288.
   PubMed Web of Science ®Google Scholar
• Basavapathruni A, Olhava EJ, Daigle SR, et al. Nonclinical pharmacokinetics and metabolism of EPZ-5676, a novel DOT1L histone methyltransferase inhibitor. Biopharm Drug Dispos. 2014 May;35(4):237–252.
   PubMed Web of Science ®Google Scholar
• Williams AB, Nguyen B, Li L, et al. Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors. Leukemia. 2013 Jan;27(1):48–55.
   PubMed Web of Science ®Google Scholar
• Pauwels D, Sweron B, Cools J. The N676D and G697R mutations in the kinase domain of FLT3 confer resistance to the inhibitor AC220. Haematologica. 2012 Nov;97(11):1773–1774.
   PubMed Web of Science ®Google Scholar
• Campbell CT, Haladyna JN, Drubin DA, et al. Mechanisms of pinometostat (EPZ-5676) treatment-emergent resistance in MLL-rearranged leukemia. Mol Cancer Ther. 2017 Aug;16(8):1669–1679.
   PubMed Web of Science ®Google Scholar
• Stein EM, Garcia-Manero G, Rizzieri DA, et al. A phase 1 study of the DOT1L inhibitor, pinometostat (EPZ-5676), in adults with relapsed or refractory leukemia: safety, clinical activity, exposure and target inhibition. blood. 2015 december 3;126(23):2547.
   Web of Science ®Google Scholar
• Rau RE, Rodriguez BA, Luo M, et al. DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia. Blood. 2016 Aug 18;128(7):971–981.
   PubMed Web of Science ®Google Scholar
• Gilan O, Lam EY, Becher I, et al. Functional interdependence of BRD4 and DOT1L in MLL leukemia. Nat Struct Mol Biol. 2016 Jul;23(7):673–681.
   PubMed Web of Science ®Google Scholar
• Klaus CR, Iwanowicz D, Johnston D, et al. DOT1L inhibitor EPZ-5676 displays synergistic antiproliferative activity in combination with standard of care drugs and hypomethylating agents in MLL-rearranged leukemia cells. J Pharmacol Exp Ther. 2014 Sep;350(3):646–656.
   PubMed Web of Science ®Google Scholar